A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05023980)

🧪 Interventions in This Study

• Pirtobrutinib (DRUG)
• Bendamustine (DRUG)
• Rituximab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (108 Sites)

Showing the first 25 of 108 sites.

• California Research Institute — Los Angeles, California
• Innovative Clinical Research Institute — Whittier, California
• Oncology-Hematology Associates of West Broward — Coral Springs, Florida
• New Jersey Center for Cancer Research — Brick, New Jersey
• Clinical Research Alliance, Inc. — Westbury, New York
• Liverpool Hospital — Liverpool, New South Wales
• Westmead Hospital — Wentworthville, New South Wales
• Peninsula Private Hospital — Frankston, Victoria
• Uniklinikum Salzburg — Salzburg,
• Klinik Ottakring — Vienna,
• Hospital de Clinicas de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Irmandade da Santa Casa de Misericórdia de Porto Alegre — Porto Alegre, Rio Grande do Sul
• Centro Gaucho Integrado - Mae de Deus Center — Porto Alegre, Rio Grande do Sul
• Hemocentro Unicamp — Campinas, São Paulo
• Fundação Doutor Amaral Carvalho — Jaú, São Paulo
• UMHAT "Sveti Georgi" EAD — Plovdiv,
• UMHAT 'Sv. Ivan Rilski', EAD — Sofia,
• "SHATHD" EAD, Sofia — Sofia,
• UMHAT - Prof. Dr. Stoyan Kirkovich" AD — Stara Zagora,
• Anhui Provincial Cancer Hospital — Hefei, Anhui
• Peking University First Hospital — Beijing, Beijing Municipality
• Peking University Third Hospital — Beijing, Beijing Municipality
• The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong
• Union Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei
• Xiangya Hospital Central South University — Changsha, Hunan

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Lymphocytic Leukemia

• Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia — Houston, Texas
• Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia — Rochester, Minnesota
• A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) — Anchorage, Alaska
• Economic Analysis of Alliance A041202 CLL Study — Calgary, Alberta
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Chandler, Arizona
• Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) — Phoenix, Arizona

Explore by condition: All Chronic Lymphocytic Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.